Anaemia And Breast Feeding.
Although breast-feeding is approximately considered the best modus vivendi to nourish an infant, new research suggests that in the long term it may lead to lower levels of iron. "What we found was that over a year of age, the longer the young gentleman is breast-fed, the greater the risk of iron deficiency," said the study's prima donna author, Dr Jonathon Maguire, pediatrician and scientist at Li Ka Shing Knowledge Institute at St Michael's Hospital at the University of Toronto in Canada. The study, released online April 15, 2013 in the memoir Pediatrics, did not, however, allot a statistical relation between the duration of breast-feeding and iron deficiency anemia.
Anemia is a mould in which the body has too few red blood cells. Iron is an important nutrient, especially in children. It is dynamic for normal development of the nervous system and brain, according to background information included in the study.
Growth spurts burgeon the body's need for iron, and infancy is a time of rapid growth. The World Health Organization recommends breast-feeding exclusively for the to begin six months of life and then introducing complementary foods. The WHO endorses continued breast-feeding up to 2 years of mature or longer, according to the study.
Previous studies have found an comradeship between breast-feeding for longer than six months and reduced iron stores in youngsters. The course study sought to confirm that link in young, fine fettle urban children. The researchers included data from nearly 1650 children between 1 and 6 years old, with an commonplace age of about 3 years.
Showing posts with label breast. Show all posts
Showing posts with label breast. Show all posts
Tuesday 23 May 2017
Sunday 21 May 2017
Lymphedema Does Not Appear Because Of The Strength Exercises After The Removal Of Breast Cancer
Lymphedema Does Not Appear Because Of The Strength Exercises After The Removal Of Breast Cancer.
Contrary to usual wisdom, lifting weights doesn't cause chest cancer survivors to come about the painful, arm-swelling condition known as lymphedema, original research suggests. There's a hint that weight-lifting might even help prevent lymphedema, but more inquiry is needed to say that for sure, the researchers said. Breast cancer-related lymphedema is caused by an gathering of lymph fluid after surgical removal of the lymph nodes and/or radiation. It is a grave condition that may cause arm swelling, awkwardness and discomfort.
And "Lymphedema is something women deep down fear after breast cancer, and the guidance has been not to lift anything heavier even than a purse," said Kathryn H Schmitz, assume command author of the study to be presented Wednesday at the San Antonio Breast Cancer Symposium. "But to forecast women to not use that affected arm without giving them a prescription for a personal valet is an absurdist principle".
A former study done by the same team of researchers found that exercise actually stabilized symptoms amongst women who already had lymphedema. "We really wanted to put the last stamp on this to say, 'Hey, it is not only secured but may actually be good for their arms," said Schmitz, who is an associate professor of family prescription and community health at the University of Pennsylvania School of Medicine and a member of the Abramson Cancer Center in Philadelphia.
And "It's almost similar to a paradigm shift," said Lee Jones, scientific boss of the Duke Cancer Institute's Center for Cancer Survivorship in Durham, NC "Low-volume defences training does not exacerbate lymphedema". To see if a slowly progressive rehabilitation program using weights would relief the arm, 134 breast cancer survivors with at least two lymph nodes removed but no put one's signature on of lymphedema who had been diagnosed one to five years before entry in the study were randomly selected to participate in one of two groups.
Contrary to usual wisdom, lifting weights doesn't cause chest cancer survivors to come about the painful, arm-swelling condition known as lymphedema, original research suggests. There's a hint that weight-lifting might even help prevent lymphedema, but more inquiry is needed to say that for sure, the researchers said. Breast cancer-related lymphedema is caused by an gathering of lymph fluid after surgical removal of the lymph nodes and/or radiation. It is a grave condition that may cause arm swelling, awkwardness and discomfort.
And "Lymphedema is something women deep down fear after breast cancer, and the guidance has been not to lift anything heavier even than a purse," said Kathryn H Schmitz, assume command author of the study to be presented Wednesday at the San Antonio Breast Cancer Symposium. "But to forecast women to not use that affected arm without giving them a prescription for a personal valet is an absurdist principle".
A former study done by the same team of researchers found that exercise actually stabilized symptoms amongst women who already had lymphedema. "We really wanted to put the last stamp on this to say, 'Hey, it is not only secured but may actually be good for their arms," said Schmitz, who is an associate professor of family prescription and community health at the University of Pennsylvania School of Medicine and a member of the Abramson Cancer Center in Philadelphia.
And "It's almost similar to a paradigm shift," said Lee Jones, scientific boss of the Duke Cancer Institute's Center for Cancer Survivorship in Durham, NC "Low-volume defences training does not exacerbate lymphedema". To see if a slowly progressive rehabilitation program using weights would relief the arm, 134 breast cancer survivors with at least two lymph nodes removed but no put one's signature on of lymphedema who had been diagnosed one to five years before entry in the study were randomly selected to participate in one of two groups.
Friday 12 May 2017
Sports Prevents Breast Cancer
Sports Prevents Breast Cancer.
Vigorous perturb on a regular basis might better protect black women against an aggressive form of breast cancer, researchers have found in Dec 2013. The unique study included nearly 45000 black women, aged 30 and older, who were followed for nearly 20 years. Those who tied up in vigorous exercise for a lifetime average of three or more hours a week were 47 percent less proper to develop so-called estrogen receptor-negative breast cancer compared with those who exercised an usual of one hour per week, the investigators found.
This type of heart of hearts cancer, which includes HER2-positive and triple-negative tumors, is linked to both higher incidence and death jeopardy in black women, compared to white women. These estrogen receptor-negative tumors do not react to the types of hormone therapies used to treat tumors that have the estrogen receptor, the researchers said in a Georgetown University Medical Center story release.
Vigorous perturb on a regular basis might better protect black women against an aggressive form of breast cancer, researchers have found in Dec 2013. The unique study included nearly 45000 black women, aged 30 and older, who were followed for nearly 20 years. Those who tied up in vigorous exercise for a lifetime average of three or more hours a week were 47 percent less proper to develop so-called estrogen receptor-negative breast cancer compared with those who exercised an usual of one hour per week, the investigators found.
This type of heart of hearts cancer, which includes HER2-positive and triple-negative tumors, is linked to both higher incidence and death jeopardy in black women, compared to white women. These estrogen receptor-negative tumors do not react to the types of hormone therapies used to treat tumors that have the estrogen receptor, the researchers said in a Georgetown University Medical Center story release.
Tuesday 2 May 2017
Both Raloxifene And Tamoxifen Is Protect Against Breast Cancer
Both Raloxifene And Tamoxifen Is Protect Against Breast Cancer.
The up-to-date results from a landmark, long-running over find that both tamoxifen and raloxifene aid prevent breast cancer in postmenopausal women, although some differences are starting to emerge between the two drugs. Raloxifene (Evista), from the beginning an osteoporosis drug, was less effective at preventing invasive breast cancer and more striking against noninvasive breast cancer than tamoxifen.
But raloxifene compensated by having fewer pretension effects and a lower likelihood of causing uterine cancer than its older cousin. Both drugs masterpiece by interfering with the ability of estrogen to fuel tumor growth. "The results of this update are genuine news for postmenopausal women.
It reconfirms that both of these drugs are very reasonable options to consider to cut down the risk of breast cancer in postmenopausal women," said Dr D Lawrence Wickerham, fellow-worker chairman of the breast cancer group in the National Surgical Adjuvant Breast and Bowel Project (NSABP), a clinical trials cooperative group. "We are light of some differences emerging, but both are effective".
Tamoxifen also stays in the body longer, contribution protection for a longer time after women have stopped taking the drug, the contemplation found. "Both drugs still offer significant protection against breast cancer. The fundamental difference with the longer-term follow-up is that the benefit of protection afforded by raloxifene looks like it's tailing after women bring to a stop taking the drug, whereas the effect of tamoxifen persists," said Dr Mary Daly, chairwoman of clinical genetics at Fox Chase Cancer Center in Philadelphia.
This also means the toxicities of tamoxifen keep up after women stay taking that drug, she pointed out. The findings were presented Monday at the American Association for Cancer Research annual converging in Washington, DC, and simultaneously published online in the register Cancer Prevention Research.
The up-to-date results from a landmark, long-running over find that both tamoxifen and raloxifene aid prevent breast cancer in postmenopausal women, although some differences are starting to emerge between the two drugs. Raloxifene (Evista), from the beginning an osteoporosis drug, was less effective at preventing invasive breast cancer and more striking against noninvasive breast cancer than tamoxifen.
But raloxifene compensated by having fewer pretension effects and a lower likelihood of causing uterine cancer than its older cousin. Both drugs masterpiece by interfering with the ability of estrogen to fuel tumor growth. "The results of this update are genuine news for postmenopausal women.
It reconfirms that both of these drugs are very reasonable options to consider to cut down the risk of breast cancer in postmenopausal women," said Dr D Lawrence Wickerham, fellow-worker chairman of the breast cancer group in the National Surgical Adjuvant Breast and Bowel Project (NSABP), a clinical trials cooperative group. "We are light of some differences emerging, but both are effective".
Tamoxifen also stays in the body longer, contribution protection for a longer time after women have stopped taking the drug, the contemplation found. "Both drugs still offer significant protection against breast cancer. The fundamental difference with the longer-term follow-up is that the benefit of protection afforded by raloxifene looks like it's tailing after women bring to a stop taking the drug, whereas the effect of tamoxifen persists," said Dr Mary Daly, chairwoman of clinical genetics at Fox Chase Cancer Center in Philadelphia.
This also means the toxicities of tamoxifen keep up after women stay taking that drug, she pointed out. The findings were presented Monday at the American Association for Cancer Research annual converging in Washington, DC, and simultaneously published online in the register Cancer Prevention Research.
Sunday 19 March 2017
A New Approach To The Regularity Of Mammography
A New Approach To The Regularity Of Mammography.
A revitalized backfire challenges the 2009 recommendation from the US Preventive Services Task Force that women between 40 and 49 who are not at lofty risk of breast cancer can probably wait to get a mammogram until 50, and even then only needfulness the exam every two years. A well-known Harvard Medical School radiologist, script in the July issue of Radiology, says telling women to wait until 50 is bedsitter out wrong. The task force recommendations, he says, are based on faulty realm and should be revised or withdrawn.
So "We know from the scientific studies that screening saves a lot of lives, and it saves lives to each women in their 40s," said Dr Daniel B Kopans, a professor of radiology at Harvard Medical School and older radiologist in the breast imaging division at Massachusetts General Hospital in Boston. The US Preventive Services Task Force (USPSTF) said its recommendation, which sparked a firestorm of controversy, was based in art and would keep many women each year from superfluous worry and treatment.
But the guidelines left most women confused. The American Cancer Society continued to suggest annual mammograms for women in their 40s, and young breast cancer survivors shared great stories about how screening saved their lives. One main question with the guidelines is that the USPSTF relied on incorrect methods of analyzing data from breast cancer studies.
The gamble of breast cancer starts rising gradually during the 40s, 50s and gets higher still during the 60s. But the figures used by the USPSTF lumped women between 40 and 49 into one group, and women between 50 and 59 in another group, and predetermined those in the younger group were much less likely to develop tit cancer than those in the older group.
That may be true except that assigning age 50 as the "right" maturity for mammography is arbitrary. "A woman who is 49 is similar biologically to a woman who is 51. Breast cancer doesn't observe your age. There is nothing that changes abruptly at age 50".
Other problems with the USPSTF guidelines cover the following. The guidelines cite research that shows mammograms are important for a 15 percent reduction in mortality. That's an underestimate. Other studies show screening women in their 40s can ease deaths by as much as 44 percent. Sparing women from unnecessary annoy over false positives is a poor reason for not screening, since dying of breast cancer is a far worse fate. "They made the self-serving decision that women in their 40s couldn't tolerate the anxiety of being called back because of a dubious screening study, even though when you ask women who've been through it, most are pleased there was nothing wrong, and studies show they will come back for their next screening even more religiously. The job force took the decision away from women. It's incredibly paternalistic". The business force recommendation to screen only high-risk women in their 40s will oversight the 75 percent of breast cancers that occur among women who would not be considered high risk, that is, they don't have a fervid family history of the disease and they don't have the BRCA1 or BRCA2 genes known to amplify cancer risk.
A revitalized backfire challenges the 2009 recommendation from the US Preventive Services Task Force that women between 40 and 49 who are not at lofty risk of breast cancer can probably wait to get a mammogram until 50, and even then only needfulness the exam every two years. A well-known Harvard Medical School radiologist, script in the July issue of Radiology, says telling women to wait until 50 is bedsitter out wrong. The task force recommendations, he says, are based on faulty realm and should be revised or withdrawn.
So "We know from the scientific studies that screening saves a lot of lives, and it saves lives to each women in their 40s," said Dr Daniel B Kopans, a professor of radiology at Harvard Medical School and older radiologist in the breast imaging division at Massachusetts General Hospital in Boston. The US Preventive Services Task Force (USPSTF) said its recommendation, which sparked a firestorm of controversy, was based in art and would keep many women each year from superfluous worry and treatment.
But the guidelines left most women confused. The American Cancer Society continued to suggest annual mammograms for women in their 40s, and young breast cancer survivors shared great stories about how screening saved their lives. One main question with the guidelines is that the USPSTF relied on incorrect methods of analyzing data from breast cancer studies.
The gamble of breast cancer starts rising gradually during the 40s, 50s and gets higher still during the 60s. But the figures used by the USPSTF lumped women between 40 and 49 into one group, and women between 50 and 59 in another group, and predetermined those in the younger group were much less likely to develop tit cancer than those in the older group.
That may be true except that assigning age 50 as the "right" maturity for mammography is arbitrary. "A woman who is 49 is similar biologically to a woman who is 51. Breast cancer doesn't observe your age. There is nothing that changes abruptly at age 50".
Other problems with the USPSTF guidelines cover the following. The guidelines cite research that shows mammograms are important for a 15 percent reduction in mortality. That's an underestimate. Other studies show screening women in their 40s can ease deaths by as much as 44 percent. Sparing women from unnecessary annoy over false positives is a poor reason for not screening, since dying of breast cancer is a far worse fate. "They made the self-serving decision that women in their 40s couldn't tolerate the anxiety of being called back because of a dubious screening study, even though when you ask women who've been through it, most are pleased there was nothing wrong, and studies show they will come back for their next screening even more religiously. The job force took the decision away from women. It's incredibly paternalistic". The business force recommendation to screen only high-risk women in their 40s will oversight the 75 percent of breast cancers that occur among women who would not be considered high risk, that is, they don't have a fervid family history of the disease and they don't have the BRCA1 or BRCA2 genes known to amplify cancer risk.
Friday 6 January 2017
The Use Of Triple Antiretroviral Drugs During Feeding Protects The Child From HIV
The Use Of Triple Antiretroviral Drugs During Feeding Protects The Child From HIV.
In sub-Saharan Africa, many mothers with HIV are faced with an horrible choice: breast-feed their babies and hazard infecting them or use formula, which is often out of impress because of cost or can fall ill the baby due to a lack of clean drinking water. Now, two new studies win that giving pregnant and nursing women triple antiretroviral drug therapy, or treating breast-fed infants with an antiretroviral medication, can dramatically write transmission rates, enabling moms to both breast-feed and to cover nearly all children from infection.
In one study, a combination antiretroviral drug therapy given to pregnant and breast-feeding women in Botswana kept all but 1 percent of babies from contracting the infection during six months of breast-feeding. Without the upper therapy, about 25 percent of babies would become infected with the AIDS-causing virus, according to researchers from the Harvard School of Public Health.
A back study, led by researchers from the University of North Carolina at Chapel Hill, found that giving babies an antiretroviral antidepressant once a light of day during their first six months of being reduced the transmission rate to 1,7 percent. Both studies are published in the June 17 consummation of the New England Journal of Medicine.
In the United States, HIV-positive women are typically given antiretrovirals during pregnancy to leave alone passing HIV to their babies in utero or during labor and delivery. After the pet is born, women are advised to use formula instead of breast-feeding for the same reason, said major study author Dr Charles M van der Horst, a professor of pharmaceutical and infectious diseases at the University of North Carolina at Chapel Hill.
That works well in developed nations where prescription is easy to come by and a clean water supply is readily available, van der Horst said. But throughout much of sub-Saharan Africa, salt water supplies can be contaminated by bacteria and other pathogens that, especially in the truancy of good medical care, can cause diarrheal illnesses that can be deadly for babies.
Previous experimentation has shown that formula-fed babies in the region die at a high rate from pneumonia or diarrheal disease, leaving women in a Catch-22. "In Africa, tit milk is absolutely essential for the first six months of life," van der Horst said. "Mothers there recollect that. It was a 'between a overwhelm and a hard place' issue for them".
In sub-Saharan Africa, many mothers with HIV are faced with an horrible choice: breast-feed their babies and hazard infecting them or use formula, which is often out of impress because of cost or can fall ill the baby due to a lack of clean drinking water. Now, two new studies win that giving pregnant and nursing women triple antiretroviral drug therapy, or treating breast-fed infants with an antiretroviral medication, can dramatically write transmission rates, enabling moms to both breast-feed and to cover nearly all children from infection.
In one study, a combination antiretroviral drug therapy given to pregnant and breast-feeding women in Botswana kept all but 1 percent of babies from contracting the infection during six months of breast-feeding. Without the upper therapy, about 25 percent of babies would become infected with the AIDS-causing virus, according to researchers from the Harvard School of Public Health.
A back study, led by researchers from the University of North Carolina at Chapel Hill, found that giving babies an antiretroviral antidepressant once a light of day during their first six months of being reduced the transmission rate to 1,7 percent. Both studies are published in the June 17 consummation of the New England Journal of Medicine.
In the United States, HIV-positive women are typically given antiretrovirals during pregnancy to leave alone passing HIV to their babies in utero or during labor and delivery. After the pet is born, women are advised to use formula instead of breast-feeding for the same reason, said major study author Dr Charles M van der Horst, a professor of pharmaceutical and infectious diseases at the University of North Carolina at Chapel Hill.
That works well in developed nations where prescription is easy to come by and a clean water supply is readily available, van der Horst said. But throughout much of sub-Saharan Africa, salt water supplies can be contaminated by bacteria and other pathogens that, especially in the truancy of good medical care, can cause diarrheal illnesses that can be deadly for babies.
Previous experimentation has shown that formula-fed babies in the region die at a high rate from pneumonia or diarrheal disease, leaving women in a Catch-22. "In Africa, tit milk is absolutely essential for the first six months of life," van der Horst said. "Mothers there recollect that. It was a 'between a overwhelm and a hard place' issue for them".
Thursday 9 June 2016
Effects Of Some Industrial Chemicals To Increase The Risk Of Breast Cancer
Effects Of Some Industrial Chemicals To Increase The Risk Of Breast Cancer.
The children of women who are exposed to fixed industrial chemicals while with child are at an increased jeopardize for developing breast cancer as adults, a new animal muse about suggests. The chemicals - bisphenol-A (BPA) and diethylstilbestrol (DES) - are mostly produced for industrial manufacturing purposes, and are known for interfering with hormonal and metabolic processes, while alarming neurological and immune function, among both people and animals.
So "BPA is a weak estrogen and DES is a qualified estrogen, yet our study shows both have a profound effect on gene expression in the mammary gland titty throughout life," study author Dr Hugh Taylor, from the Yale University School of Medicine in New Haven, said in a account release from the Endocrine Society. "All estrogens, even 'weak' ones, can change the development of the breast and ultimately place adult women who were exposed to them prenatally at gamble of breast cancer".
The findings will be published in the June issue of Hormones & Cancer, the fortnightly of the Endocrine Society. The authors draw their conclusions from work with parturient mice who were exposed to both BPA and DES. Once reaching adulthood, the offspring were found to produce higher than general levels of a protein involved in gene regulation, called EZH2.
The children of women who are exposed to fixed industrial chemicals while with child are at an increased jeopardize for developing breast cancer as adults, a new animal muse about suggests. The chemicals - bisphenol-A (BPA) and diethylstilbestrol (DES) - are mostly produced for industrial manufacturing purposes, and are known for interfering with hormonal and metabolic processes, while alarming neurological and immune function, among both people and animals.
So "BPA is a weak estrogen and DES is a qualified estrogen, yet our study shows both have a profound effect on gene expression in the mammary gland titty throughout life," study author Dr Hugh Taylor, from the Yale University School of Medicine in New Haven, said in a account release from the Endocrine Society. "All estrogens, even 'weak' ones, can change the development of the breast and ultimately place adult women who were exposed to them prenatally at gamble of breast cancer".
The findings will be published in the June issue of Hormones & Cancer, the fortnightly of the Endocrine Society. The authors draw their conclusions from work with parturient mice who were exposed to both BPA and DES. Once reaching adulthood, the offspring were found to produce higher than general levels of a protein involved in gene regulation, called EZH2.
Thursday 2 June 2016
Joint Pain And Cancer
Joint Pain And Cancer.
Exercise might hand breast cancer survivors support the joint pain that is a side effect of their medications, researchers say at Dec 2013. A young study included patients who were taking aromatase inhibitor drugs, such as Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane). Five years of healing with these drugs is recommended for survivors who had stages 1, 2 or 3 hormone receptor-positive chest cancers. This physique of the disease accounts for nearly 70 percent of newly diagnosed breast cancer cases.
Nearly half of those who carry these medications, however, experience joint pain and stiffness. These side things are the most common reason patients stop taking the drugs, the study authors said in an American Association for Cancer Research dope release. In this study, breast cancer survivors who were taking aromatase inhibitors and had mutual pain were divided randomly into two groups.
Exercise might hand breast cancer survivors support the joint pain that is a side effect of their medications, researchers say at Dec 2013. A young study included patients who were taking aromatase inhibitor drugs, such as Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane). Five years of healing with these drugs is recommended for survivors who had stages 1, 2 or 3 hormone receptor-positive chest cancers. This physique of the disease accounts for nearly 70 percent of newly diagnosed breast cancer cases.
Nearly half of those who carry these medications, however, experience joint pain and stiffness. These side things are the most common reason patients stop taking the drugs, the study authors said in an American Association for Cancer Research dope release. In this study, breast cancer survivors who were taking aromatase inhibitors and had mutual pain were divided randomly into two groups.
Saturday 17 October 2015
A Used Breast Pump Can Carry Infectious Diseases
A Used Breast Pump Can Carry Infectious Diseases.
Women who are breast-feeding should hire precautions when deciding what epitome of breast pump to use, particularly if they are looking at buying or renting a used or second-hand pump, according to a new report, which was released Jan 15, 2013 from the US Food and Drug Administration. Although core pumps can range from single, vade-mecum pumps to double, electric-powered models, all have a few basic parts, including a breast defend that fits over the nipple, a pump that creates a vacuum to express the milk and a detachable container for collecting the milk, Kathryn Daws-Kopp, an FDA electrical engineer, said in the report. The FDA oversees the aegis and effectiveness of these devices.
Although women can acquire breast pumps, many hospitals, medical contribute stores and lactation consultants rent breast pumps that can be used by multiple women. The FDA advised all women who use rented or worn pumps to buy an accessory trappings with new breast shields and tubing - even if the existing kit looks clean. Potentially transmissible particles may linger in a breast pump or its accessories for a long time after a woman finishes using it.
These germs can infect the tot or the next woman who uses that pump, said Dr Michael Cummings, an obstetrician and gynecologist with the FDA. The report, published on the Consumer Updates errand-boy of the FDA's website, offers the following tips to safeguard that a breast pump is clean. Rinse each adjunct that comes into contact with breast milk in cool water immediately after pumping.
Wash each accessory singly using liquid dishwashing soap and warm water, and rinse each piece in hot water for 10 to 15 seconds. Allow each attachment to air-dry completely on a clean towel or drying rack. The FDA famous that women who rent breast pumps should request that all parts of their question be cleaned, disinfected and sterilized according to the manufacturer's directions.
Women who are breast-feeding should hire precautions when deciding what epitome of breast pump to use, particularly if they are looking at buying or renting a used or second-hand pump, according to a new report, which was released Jan 15, 2013 from the US Food and Drug Administration. Although core pumps can range from single, vade-mecum pumps to double, electric-powered models, all have a few basic parts, including a breast defend that fits over the nipple, a pump that creates a vacuum to express the milk and a detachable container for collecting the milk, Kathryn Daws-Kopp, an FDA electrical engineer, said in the report. The FDA oversees the aegis and effectiveness of these devices.
Although women can acquire breast pumps, many hospitals, medical contribute stores and lactation consultants rent breast pumps that can be used by multiple women. The FDA advised all women who use rented or worn pumps to buy an accessory trappings with new breast shields and tubing - even if the existing kit looks clean. Potentially transmissible particles may linger in a breast pump or its accessories for a long time after a woman finishes using it.
These germs can infect the tot or the next woman who uses that pump, said Dr Michael Cummings, an obstetrician and gynecologist with the FDA. The report, published on the Consumer Updates errand-boy of the FDA's website, offers the following tips to safeguard that a breast pump is clean. Rinse each adjunct that comes into contact with breast milk in cool water immediately after pumping.
Wash each accessory singly using liquid dishwashing soap and warm water, and rinse each piece in hot water for 10 to 15 seconds. Allow each attachment to air-dry completely on a clean towel or drying rack. The FDA famous that women who rent breast pumps should request that all parts of their question be cleaned, disinfected and sterilized according to the manufacturer's directions.
Saturday 16 May 2015
Early Breast Cancer Survival
Early Breast Cancer Survival.
Your chances of being diagnosed with initially core cancer, as well as surviving it, vary greatly depending on your race and ethnicity, a new observe indicates. "It had been assumed lately that we could explain the differences in outcome by access to care," said edge researcher Dr Steven Narod, Canada research chair in breast cancer and a professor of unrestricted health at the University of Toronto. In previous studies, experts have found that some ethnic groups have better access to care. But that's not the undamaged story.
His team discovered that racially based biological differences, such as the expanding of cancer to the lymph nodes or having an aggressive ilk of breast cancer known as triple-negative, explain much of the disparity. "Ethnicity is just as likely to predict who will dynamic and who will die from early breast cancer as other factors, like the cancer's appearance and treatment". In his study, nearly 374000 women who were diagnosed with invasive bosom cancer between 2004 and 2011 were followed for about three years.
The researchers divided the women into eight ethnological or ethnic groups and looked at the types of tumors, how pugnacious the tumors were and whether they had spread. During the study period, Japanese women were more fitting to be diagnosed at stage 1 than white women were, with 56 percent of Japanese women declaration out they had cancer early, compared to 51 percent of white women. But only 37 percent of foul women and 40 percent of South Asian women got an early diagnosis, the findings showed.
Your chances of being diagnosed with initially core cancer, as well as surviving it, vary greatly depending on your race and ethnicity, a new observe indicates. "It had been assumed lately that we could explain the differences in outcome by access to care," said edge researcher Dr Steven Narod, Canada research chair in breast cancer and a professor of unrestricted health at the University of Toronto. In previous studies, experts have found that some ethnic groups have better access to care. But that's not the undamaged story.
His team discovered that racially based biological differences, such as the expanding of cancer to the lymph nodes or having an aggressive ilk of breast cancer known as triple-negative, explain much of the disparity. "Ethnicity is just as likely to predict who will dynamic and who will die from early breast cancer as other factors, like the cancer's appearance and treatment". In his study, nearly 374000 women who were diagnosed with invasive bosom cancer between 2004 and 2011 were followed for about three years.
The researchers divided the women into eight ethnological or ethnic groups and looked at the types of tumors, how pugnacious the tumors were and whether they had spread. During the study period, Japanese women were more fitting to be diagnosed at stage 1 than white women were, with 56 percent of Japanese women declaration out they had cancer early, compared to 51 percent of white women. But only 37 percent of foul women and 40 percent of South Asian women got an early diagnosis, the findings showed.
Sunday 21 December 2014
Children Who Were Breastfed In The Future Much Better In School
Children Who Were Breastfed In The Future Much Better In School.
Adding to reports that breast-feeding boosts perspicacity health, a imaginative learning finds that infants breast-fed for six months or longer, especially boys, do considerably better in school at ripen 10 compared to bottle-fed tots, according to a new study. "Breast-feeding should be promoted for both boys and girls for its egregious benefits," said study leader Wendy Oddy, a researcher at the Telethon Institute for Child Health Research in Perth, Australia. For the study, published online Dec 20, 2010 in Pediatrics, she and her colleagues looked at the visionary scores at grow old 10 of more than a thousand children whose mothers had enrolled in an evolving study in western Australia.
After adjusting for such factors as gender, genus income, maternal factors and early stimulation at home, such as reading to children, they estimated the links between breast-feeding and edifying outcomes. Babies who were mainly breast-fed for six months or longer had higher unpractical scores on standardized tests than those breast-fed fewer than six months, she found. But the result varied by gender, and the improvements were only significant from a statistical point of view for the boys.
The boys had better scores in math, reading, spelling and chirography if they were breast-fed six months or longer. Girls breast-fed for six months or longer had a selfish but statistically insignificant benefit in reading scores. The common sense for the gender differences is unclear, but Oddy speculates that the protective role of breast tap on the brain and its later consequences for language development may have greater benefits for boys because they are more vulnerable during vital development periods.
Another possibility has to do with the positive effect of breastfeeding on the mother-child relationship, she said. "A several of studies found that boys are more reliant than girls on maternal attention and encouragement for the acquisition of cognitive and dialect skills. If breastfeeding facilitates mother-child interactions, then we would expect the positive junk of this bond to be greater in males compared with females, as we observed".
Adding to reports that breast-feeding boosts perspicacity health, a imaginative learning finds that infants breast-fed for six months or longer, especially boys, do considerably better in school at ripen 10 compared to bottle-fed tots, according to a new study. "Breast-feeding should be promoted for both boys and girls for its egregious benefits," said study leader Wendy Oddy, a researcher at the Telethon Institute for Child Health Research in Perth, Australia. For the study, published online Dec 20, 2010 in Pediatrics, she and her colleagues looked at the visionary scores at grow old 10 of more than a thousand children whose mothers had enrolled in an evolving study in western Australia.
After adjusting for such factors as gender, genus income, maternal factors and early stimulation at home, such as reading to children, they estimated the links between breast-feeding and edifying outcomes. Babies who were mainly breast-fed for six months or longer had higher unpractical scores on standardized tests than those breast-fed fewer than six months, she found. But the result varied by gender, and the improvements were only significant from a statistical point of view for the boys.
The boys had better scores in math, reading, spelling and chirography if they were breast-fed six months or longer. Girls breast-fed for six months or longer had a selfish but statistically insignificant benefit in reading scores. The common sense for the gender differences is unclear, but Oddy speculates that the protective role of breast tap on the brain and its later consequences for language development may have greater benefits for boys because they are more vulnerable during vital development periods.
Another possibility has to do with the positive effect of breastfeeding on the mother-child relationship, she said. "A several of studies found that boys are more reliant than girls on maternal attention and encouragement for the acquisition of cognitive and dialect skills. If breastfeeding facilitates mother-child interactions, then we would expect the positive junk of this bond to be greater in males compared with females, as we observed".
Monday 16 December 2013
Omnitarg And Herceptin Could Save Women Without Chemotherapy From Breast Cancer
Omnitarg And Herceptin Could Save Women Without Chemotherapy From Breast Cancer.
Combinations of targeted therapies for an especially martial archetype of breast cancer could potentially usher the mass of affected patients into remission, researchers at a major breast cancer meeting said Friday. Presenting results from three trials at the annual San Antonio Breast Cancer Symposium, scientists explained that administering two or more drugs designed to examine HER2-positive tumors resulted in much higher deliverance rates than doses of any one opiate or standard chemotherapy alone. Given to patients several weeks before cancer surgery, with or without chemotherapy, the medications often shrank tumors dramatically or eradicated them altogether, the researchers said.
HER2-positive cancer is flexible to a protein called charitable epidermal lump factor receptor 2, which promotes the growth of malignant cells. Drugs that specifically objective HER2 cells - including Herceptin, Tykerb and Omnitarg - have been proven real on these types of tumors, which tend to be more aggressive than other breast cancers. "I think it's a very captivating era, because we've gone from a very lethal era - to a point where we might be able to cure this disease," said Dr Neil Spector, a professor of medicament at Duke University Medical Center, who moderated the symposium session.
Using Tykerb and Herceptin combined with chemotherapy before surgery, researchers followed 2,500 women with inappropriate heart cancer at 85 facilities throughout Germany. About half of these patients achieved release before surgery, said Dr Michael Untch, head of the multidisciplinary breast cancer domain at Helios Clinic in Berlin. "In a majority of these patients, we could do breast-conserving surgery where previously they were candidates for mastectomy," Untch said.
The group will continue following the patients to see if remission at surgery affects their outcome. Another weigh showed the combination of Omnitarg and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without Omnitarg. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.
Combinations of targeted therapies for an especially martial archetype of breast cancer could potentially usher the mass of affected patients into remission, researchers at a major breast cancer meeting said Friday. Presenting results from three trials at the annual San Antonio Breast Cancer Symposium, scientists explained that administering two or more drugs designed to examine HER2-positive tumors resulted in much higher deliverance rates than doses of any one opiate or standard chemotherapy alone. Given to patients several weeks before cancer surgery, with or without chemotherapy, the medications often shrank tumors dramatically or eradicated them altogether, the researchers said.
HER2-positive cancer is flexible to a protein called charitable epidermal lump factor receptor 2, which promotes the growth of malignant cells. Drugs that specifically objective HER2 cells - including Herceptin, Tykerb and Omnitarg - have been proven real on these types of tumors, which tend to be more aggressive than other breast cancers. "I think it's a very captivating era, because we've gone from a very lethal era - to a point where we might be able to cure this disease," said Dr Neil Spector, a professor of medicament at Duke University Medical Center, who moderated the symposium session.
Using Tykerb and Herceptin combined with chemotherapy before surgery, researchers followed 2,500 women with inappropriate heart cancer at 85 facilities throughout Germany. About half of these patients achieved release before surgery, said Dr Michael Untch, head of the multidisciplinary breast cancer domain at Helios Clinic in Berlin. "In a majority of these patients, we could do breast-conserving surgery where previously they were candidates for mastectomy," Untch said.
The group will continue following the patients to see if remission at surgery affects their outcome. Another weigh showed the combination of Omnitarg and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without Omnitarg. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.
Subscribe to:
Posts (Atom)